Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Peginterferon beta-1a - Biogen

Drug Profile

Peginterferon beta-1a - Biogen

Alternative Names: BIIB 017; PEG-interferon-β-1a; PEGylated INF-beta-1a - Biogen; Plegridy

Latest Information Update: 14 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen Idec
  • Developer Biogen
  • Class Interferons
  • Mechanism of Action Immunomodulators; Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis

Most Recent Events

  • 21 Jul 2022 Biogen terminates a phase III in Multiple sclerosis (In children's, In adolescents, Combination therapy) in Colombia, Jordan, South Korea, Malaysia, Mexico, Saudi Arabia, Taiwan, Thailand, Tunisia, Turkey, Estonia, Hungary and USA (SC, Injection) due to long-term difficulties faced in fulfilling enrolment commitments(NCT03870763)
  • 02 Apr 2022 Adverse events and pharmacokinetics data from a phase I trial in Multiple-sclerosis presented at the 74th Annual Meeting of the American Academy of Neurology 2022(AAN-2022)
  • 02 Apr 2022 Biogen completes phase I pharmacokinetics trial for Multiple sclerosis (In volunteers) in the USA prior to April 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top